LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

16.23 2.33

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

15.48

Максимум

16.28

Ключови измерители

By Trading Economics

Приходи

13M

-72M

Продажби

18M

38M

Марж на печалбата

-189.28

Служители

270

EBITDA

20M

-64M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+111.99% upside

Дивиденти

By Dow Jones

Следващи печалби

4.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

456M

1.3B

Предишно отваряне

13.9

Предишно затваряне

16.23

Настроения в новините

By Acuity

15%

85%

13 / 372 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.08.2025 г., 22:51 ч. UTC

Печалби

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H Rev $4.01B

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H Adj EPS $1.84

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H EPS $1.82

27.08.2025 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27.08.2025 г., 23:39 ч. UTC

Печалби

Correction to Nvidia Earnings Article -- WSJ

27.08.2025 г., 22:59 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.08.2025 г., 22:59 ч. UTC

Пазарно говорене

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27.08.2025 г., 22:58 ч. UTC

Печалби

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27.08.2025 г., 22:57 ч. UTC

Печалби

South32 FY Free Cash Flow $192 Million

27.08.2025 г., 22:56 ч. UTC

Печалби

South32 FY Total Capital Expenditure $1.35 Billion

27.08.2025 г., 22:56 ч. UTC

Печалби

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27.08.2025 г., 22:55 ч. UTC

Печалби

South32 Net Cash $123 Million at June 30

27.08.2025 г., 22:54 ч. UTC

Печалби

South32: Focused on Maintaining Strong Operating Momentum

27.08.2025 г., 22:53 ч. UTC

Печалби

South32: $144 Million Remains to be Returned to Shareholders Under Program

27.08.2025 г., 22:53 ч. UTC

Печалби

South32 Extends Capital Management Program for 12 Months

27.08.2025 г., 22:52 ч. UTC

Печалби

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27.08.2025 г., 22:51 ч. UTC

Печалби

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27.08.2025 г., 22:51 ч. UTC

Печалби

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27.08.2025 г., 22:50 ч. UTC

Печалби

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27.08.2025 г., 22:50 ч. UTC

Печалби

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27.08.2025 г., 22:45 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27.08.2025 г., 22:44 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27.08.2025 г., 22:44 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27.08.2025 г., 22:43 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27.08.2025 г., 22:43 ч. UTC

Печалби

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27.08.2025 г., 22:42 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27.08.2025 г., 22:42 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27.08.2025 г., 22:40 ч. UTC

Печалби

Sandfire Resources Net Debt $123 Million at June 30

27.08.2025 г., 22:40 ч. UTC

Печалби

Sandfire Resources FY Underlying Ebitda $527.7 Million

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

111.99% нагоре

12-месечна прогноза

Среден 33.6 USD  111.99%

Висок 56 USD

Нисък 17 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

10

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

13 / 372 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.